BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

992 related articles for article (PubMed ID: 25425629)

  • 1. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data.
    Frost FJ; Nazareth DS; Charman SC; Winstanley C; Walshaw MJ
    Ann Am Thorac Soc; 2019 Nov; 16(11):1375-1382. PubMed ID: 31319678
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
    Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
    Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
    J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 6. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
    Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
    An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
    Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
    Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries.
    Volkova N; Moy K; Evans J; Campbell D; Tian S; Simard C; Higgins M; Konstan MW; Sawicki GS; Elbert A; Charman SC; Marshall BC; Bilton D
    J Cyst Fibros; 2020 Jan; 19(1):68-79. PubMed ID: 31196670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
    Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
    Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate of Uptake of Ivacaftor Use after U.S. Food and Drug Administration Approval among Patients Enrolled in the U.S. Cystic Fibrosis Foundation Patient Registry.
    Sawicki GS; Dasenbrook E; Fink AK; Schechter MS
    Ann Am Thorac Soc; 2015 Aug; 12(8):1146-52. PubMed ID: 26073026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
    Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
    Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
    McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.